43019-84-7

Upstream product

• 536-74-3 phenylacetylene 
• 2622-14-2 tricyclohexylphosphine 
• 2883-45-6 1, 6-heptadien-4-ol 
• 14320-38-8 cyclopent-3-enol 
• 98-88-4 benzoyl chloride 

Downstream Products

• 1045861-48-0 C₂₂H₂₀O₄ 
• 1307886-65-2 C₁₃H₁₂F₂O₂ 
• 1307304-66-0 C₁₃H₁₂F₂O₂ 
• 1099656-48-0 C₆H₈F₂O 
• 1307304-67-1 C₁₃H₁₄F₂O₃S 
• 124555-33-5 (1R,3R)-3-aminocyclopentanol hydrochloride 
• 26786-36-7 ethyl 3-hydroxybicyclo[3.1.0]hexane-6-carboxylate 
• 234085-27-9 ethyl 3,3-difluorobicyclo[3.1.0]hexane-6-carboxylate 
• 1307304-69-3 C₁₀H₁₅F₂NO₂ 
• 1307304-68-2 C₂₃H₂₃F₂NO₂ 

Relevant academic research and scientific papers

Synthesis of 1,3-Cycloalkadienes from Cycloalkenes: Unprecedented Reactivity of Oxoammonium Salts

Few methods allow for the direct conversion of cycloalkenes into cycloalkadienes with high chemo- and regioselectivity. Herein, we report a convenient one-pot process for this transformation that involves the unprecedented N-preferential group transfer of N-oxoammonium salts to cycloalkenes, followed by Cope elimination, to afford cycloalkadienes at room temperature and pressure.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment o

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection of following Fomula (I). Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Ruthenium metathesis catalyst and method for producing olefin reaction product by metathesis reaction using the same

The invention has an object of safely and simply preparing a large amount of a ruthenium metathesis catalyst, which is used as a catalyst for a carbon-carbon bond formation using, particularly, a metathesis reaction. The metathesis catalyst has the following complex composition (A) or (B). The composition (A) includes RuX12(arene)(PR1R2R3) and R4CHX22, R5C≡CH or R4CHX2and a reducing agent, wherein X1and X2respectively are a halogen atom; arene is a hydrocarbon having a benzene ring; R1, R2and R3, which may be the same or different, respectively are an alkyl group having 1-8 carbon atoms, a cycloalkyl group having 3-8 carbon atoms or an optionally substituted aryl group, wherein the substituent group is an alkyl group having 1-8 carbon atoms, an alkoxy group having 1-8 carbon atoms, an alkylamino group having 1-8 carbon atoms or a halogen atom; R4is an alkyl group which has 1-8 carbon atoms and may have an ether bond or an ester bond, an optionally subsituted aryl group, wherein the substituent group is a halogen atom or a hydroxyl group; or cycloalkyl group having 3-8 carbon atoms; and R5is an optionally substituted alkyl group which has 1-8 carbon atoms and may have an ether bond or an ester bond, wherein the substituent group is a halogen atom or a hydroxyl group, an aryl group or a cycloalkyl group having 3-8 carbon atoms. The composition B includes [RuX12(arene)]2, PR1R2R3, R5C≡CH or R4CHX2and a reducing agent, wherein X1, arene, R1, R2, R3, R4and R5are the same as defined above.